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Introduction
BOC and TPV are potent NS3/4A protease inhibitors for
the treatment of chronic hepatitis C (HCV) genotype 1
infection. BOC and TPV are both substrates and strong
inhibitors of the CYP3A, therefore presenting a wide
interindividual pharmacokinetic variability and multiple
drug interactions especially with ARV such as lopinavir/r,
darunavir/r or efavirenz, thus restricting options for con-
comitant ARV therapy. We evaluated plasma concentra-
tions of coinfected and monoinfected patients treated
with BOC and TPV and the PK data of patients treated
with non recommended ARV.
Method
Data from patients whose BOC and TPV trough concen-
tration had been assessed during treatment were retrospec-
tively analyzed. Plasma concentrations were determined
using a LC-MS/MS method. Mann-Whitney U test was
used for statistics (PASW Statistics 17).
Results
Overall, 58 patients were included (84% male, median
age: 51 years (34-70)), treated with BOC (25) or TPV
(33). Thirty-two (55%) patients are coinfected (14 BOC,
18 TPV) and 26 (45%) are monoinfected (11 BOC, 15
TPV). Median (range, CV) TPV and BOC trough
concentrations were respectively, 1928 ng/mL (92-3204,
47%) and 111 ng/mL (33-903, 112%) in coinfected
patients versus 2787 ng/mL (252-5551, 54%) and
153 ng/mL (25-2658, 150%) in monoinfected patients,
which is statistically different only for TPV (p<0.05). Six
patients received non recommended ARV: 4 were trea-
ted with darunavir/r (2 BOC, 2 TPV), 1 with efavirenz
and BOC and 1 with lopinavir/r and TPV. Median
(range) TPV and BOC concentrations were respectively,
1967 ng/mL (580-3204) and 103 ng/ml (33-903) with
recommended ARV versus 1304 ng/mL (92-2565) and
146 ng/ml (65-304) with non recommended ARV.
Conclusion
This study highlights a strong interindividual variability in
BOC and TPV trough concentrations. Lower concentra-
tions were observed in coinfected patients but remaining
within the expected range, which may be explained by
drug interactions with some ARV. Hence, therapeutic
drug monitoring is useful to manage these interactions
and evaluate the risk-benefit balance of using non recom-
mended ARV in coinfected patients with advanced hepatic
disease.
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